乳腺癌保乳术后辅助质子放疗的回顾性研究:常规剂量与大分割剂量的比较
本研究回顾性比较乳腺癌保乳术后质子放疗常规剂量与大分割剂量的不良反应。2017年1月至2019年12月本中心治疗50例患者,常规剂量组14例接受50 Gy/25次后瘤床加量10 Gy/4次,大分割组36例接受40.05 Gy/15次同步整合加量48 Gy。大分割组急性放射性皮炎显著优于常规剂量组,但大分割组出现放射性肺炎和肋骨骨折。
要点
- 大分割质子放疗急性放射性皮炎显著优于常规剂量质子放疗。
- 常规剂量组未出现放射性肺炎和肋骨骨折,大分割组出现3例1级肺炎、1例2级肺炎和2例肋骨骨折。
- 两组1年和2年总生存率均为100%,常规剂量组2年无病生存率92.9%,大分割组100%。
核心结论
- 质子放疗可显著降低乳腺癌患者心脏、肺及其他器官的正常组织剂量。
- 大分割质子治疗缩短疗程,放射相关不良反应轻微,在改善急性不良反应方面优于常规质子放疗。
研究设计与样本
- 回顾性研究,纳入2017年1月至2019年12月本中心保乳术后接受质子放疗的乳腺癌患者50例。
- 按AJCC第8版分期:I期26例,II期22例,III期2例。
- 14例接受调强质子治疗50 Gy/25次后瘤床加量10 Gy/4次;36例接受40.05 Gy/15次同步整合加量48 Gy至瘤床。
主要发现
- 常规剂量组1级和2级放射性皮炎分别为35.7%和57.1%,大分割组分别为91.7%和8.3%。
- 常规剂量组和大分割组1级放射性食管炎分别为85.71%和60%。
- 常规剂量组未出现放射性肺炎和肋骨骨折;大分割组出现3例1级肺炎、1例2级肺炎和2例肋骨骨折,1例甲状腺功能减退。
- 常规剂量组1年和2年总生存率均为100%,1年和2年无病生存率分别为100%和92.9%;大分割组1年和2年总生存率和无病生存率均为100%。
- 所有患者对乳房外形满意。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare the adverse reactions of conventional-dose and hypofractionated dose of proton therapy for breast cancer. MATERIALS AND METHODS: Breast cancer patients treated with proton radiotherapy in conventional-dose or hypofractionated dose were studied retrospectively. RESULT: From January 2017 to December 2019, our center treated 50 patients following lumpectomy with proton radiotherapy. According to the AJCC 8th Edition standard, there were stage I in 26 patients, stage II in 22 patients, and stage III in 2 patients. A total of 14 patients received intensity-modulated proton therapy at a dose of 50 Gy in 25 fractions, followed by a 10 Gy 4 fractionated boost to the lumpectomy cavity, while 36 received 40.05 Gy in 15 fractions, simultaneous integrated boost (SIB) 48 Gy to the lumpectomy cavity. Median follow-up time for 40.05 Gy group was 35.6 months (15-43 months). Median follow-up time for 50 Gy group was 46.8 months (36-68 months). For acute toxicity, the grade 1 and 2 radiodermatitis in conventional-dose group were 35.7% and 57.1%, respectively. In hypofractionated dose group, the grade 1 and 2 radiodermatitis were 91.7% and 8.3%, respectively. The radiodermatitis is hypofractionneted dose better than conventional-dose significantly. Grade 1 radiation-induced esophagitis in conventional-dose group and hypofractionated dose group were 85.71% and 60%, respectively. For late toxicity, no patients developed radiation-induced pneumonitis and rib fracture in conventional-dose group. Three patients presented grade 1 pneumonitis; one patient presented graded 2 pneumonitides and two patients presented rib fracture in hypofractionated dose group. One presented hypothyroidism in hypofractionated dose group. All patients were satisfied with breast shape. The one- and two-year OS and DFS for conventional-dose group were 100 and 100; 100 and 92.9%, respectively. The one- and two-year OS and DFS for hypofractionated dose group were 100 and 100; 100 and 100%, respectively. CONCLUSION: Proton radiation therapy can significantly reduce the normal tissue dose in breast cancer patients' hearts, lungs, and other organs. Hypofractionated proton therapy shortens the treatment course with mild radiation-related adverse effects, and has a better effect on addressing the acute adverse reactions than conventional proton radiotherapy.
引用
- Hong Z, Yang Z, Mei X, et al. A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose. Radiat Oncol. 2023. PMID: 36959653. doi:10.1186/s13014-023-02213-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。